Key facts
- A second case of New World screwworm was confirmed in Zavala County, Texas.
- Canada has temporarily blocked livestock imports from Texas.
- The USDA is leading containment efforts for the screwworm parasite.
- The Dow Jones Industrial Average reached a new record high.
- Investors showed a strong preference for healthcare ETFs.
- AI adoption is a factor in the healthcare sector's performance.
- Intel's stock rallied on bullish analyst sentiment regarding AI chips.
- ZoomInfo options trading volume exceeded 20,000 contracts.
- Strategy Inc. options trading volume reached 952,761 contracts.
- Hermes options trading volume rose to 3,688 contracts.
- Mondelez International options trading volume surged to 3,842 contracts.
- AngloGold Ashanti options trading volume jumped to 4,786 contracts.
U.S. cattle futures experienced a rally, driven by concerns over potential supply chain disruptions following the confirmation of a second case of the New World screwworm parasite in Zavala County, Texas. This development has led Canada to temporarily block livestock imports from Texas. The U.S. Department of Agriculture (USDA) is spearheading containment efforts to manage the parasite's spread.
In broader market movements, the Dow Jones Industrial Average achieved a new record high. Investors demonstrated a strong inclination towards healthcare Exchange Traded Funds (ETFs), with the Health Care Select Sector SPDR Fund (XLV) being a notable example. This shift into defensive sectors is partly attributed to the increasing adoption of Artificial Intelligence (AI) within the healthcare industry.
Intel's stock saw a significant rally, bolstered by a bullish assessment from a key analyst who highlighted the company's potential in the competitive AI chip market and projected strong future performance. Meanwhile, several companies experienced substantial increases in options trading volume, signaling heightened investor interest and potential stock movements. These include ZoomInfo with over 20,000 contracts traded, Strategy Inc. with 952,761 contracts, Hermes with 3,688 contracts, Mondelez International with 3,842 contracts, and AngloGold Ashanti with 4,786 contracts.
In the animal health sector, Jim Cramer recommended Elanco Animal Health over its competitor Zoetis. Separately, Zealand Pharma's stock surged following positive Phase 3 clinical trial results for its obesity drug candidate, survodutide, which met its primary endpoints by demonstrating substantial weight loss in participants.